Navigation Links
Biopure Announces 2007 Third Quarter Financial Results
Date:8/23/2007

expenses in 2007. Partially offsetting the decline in these costs was higher salaries expense due to increased headcount.

Sales and marketing expenses increased to $341,000 for the third quarter of fiscal 2007, from $197,000 for the same period in 2006, due to strategic planning activities for Hemopure in the U.K. and to increased personnel in South Africa.

General and administrative expenses were $2.1 million for the third quarter of fiscal 2007 compared to $2.2 million for the corresponding period in 2006 due to lower insurance premiums.

Financial Condition

At July 31, 2007, Biopure had $6.3 million in cash on hand.

Recent Developments

Marketing

The increase in Hemopure sales in South Africa, while not financially significant, reflects company-led marketing and gradually increasing use of the product. Hemopure has been ordered by members of every private hospital group in South Africa at a price based on current exchange rates of approximately $830 per unit. Twenty-two public hospitals stock donated product, and the South African army is a customer. Most of the sales are to private hospitals; sales to the government are at a lower price than sales to private hospitals. Selling activities continue to promote use in surgery when suitable blood is not readily available, medically is not an option or is unacceptable and blood avoidance is requested. The South Africa marketing experience continues to give the company important commercial, clinical and marketing experience.

Compassionate Use

The company recently submitted a draft clinical study protocol to the FDA for compassionate use of Hemopure in the United States for the treatment of life-threatening or potentially life threatening anemia where red blood cell transfusion is not an option. As mentioned previously in a letter to shareholders, this is a first step in attempting to formalize the compassionate use of Hemopure without requiring the filing of an IND
'/>"/>

SOURCE Biopure Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... 28 Following the feature of the UltraPulse CO2 fractional laser ... Show , The Insider will also be featuring the ... and Trae Berns were interviewed today by The Insider . ... they have lived with for 20 years. The girls also discussed ...
... 28 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... Kentrist 41 Direct, Inc. (CK41), the Company,s joint venture ... has updated its product launch plans. The previously announced ... Mr. Savage, CK41,s new Chief Executive Officer, to impart ...
... 28 Air Products, (NYSE: APD ... at www.airproducts.com/Responsibility/2009CRAR/index.asp . "In these trying times ... improved sustainability performance for our customers and our ... Products, chairman, president and chief executive officer. ...
... the American Heart Association, "silent" or "hidden" heart attacks ... are left untreated.Saint Francis Hospital in Evanston, Ill. has ... offer a new test for chest pain patients that ... The uniqueness of the new test lies in a ...
... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
... in Health Affairs finds that a Massachusetts ... has resulted in higher costs. This predictable result confirms ... must be a part of national health reform, said ... that reform is unaffordable without a public option like ...
Cached Medicine News:Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4Health News:Air Products' 2009 Corporate Responsibility Report Now Available 2Health News:Finding Hidden Heart Attacks: Saint Francis Hospital is First in Illinois to Detect Hidden Heart Attacks With New Technology 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 3
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
... Afinion HbA1c test and the ... you reliable facts conveniently available ... them. Advising the patient can ... The HbA1c Test Cartridge contains ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: